Bill Meyer was named Chief Accounting Officer of Pacific Biosciences Of California, Inc. As of November 10, 2026, Pacific Biosciences Of California, Inc. has reported 3 leadership change filings to the SEC under Item 5.02 of Form 8-K, from July 9, 2026 to November 4, 2026, naming 1 appointment and 1 departure (Form 8-K, November 4, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Pacific Biosciences Of California, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · In / out: In · Person: Bill Meyer · Role: Chief Accounting Officer · 8-K, 2026-11-04
- · In / out: Reported · Person: not named in the filing · 8-K, 2026-08-05
- · In / out: Out · Person: Christopher M. Smith · Role: Director · 8-K, 2026-07-09
Pacific Biosciences Of California, Inc. reported changes in 3 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-07-09 to 2026-11-04. They name 2 people, with 1 appointment and 1 departure. Every row below is cited to the filing it comes from, and this page adds each new change as Pacific Biosciences Of California, Inc. files it.
Layoffs on record: about 40 jobs, latest 2026-08-05 (layoff filings and notices).
Also on the record for Pacific Biosciences Of California, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| November 9, 2026 | Stake report, Schedule 13G, by THE GOLDMAN SACHS GROUP, INC. | 7.6% of the class | 5%+ stakes | Source |
| November 6, 2026 | Stake report, Schedule 13G, by T. Rowe Price Associates, Inc. | 10.8% of the class | 5%+ stakes | Source |
| August 14, 2026 | Stake report, Schedule 13G/A, by ARK Investment Management LLC | 9.59% of the class | 5%+ stakes | Source |
| March 27, 2026 | Stake report, Schedule 13G/A, by The Vanguard Group | — | 5%+ stakes | Source |
| February 3, 2026 | Stake report, Schedule 13G/A, by ARK Investment Management LLC | 12.34% of the class | 5%+ stakes | Source |
| November 14, 2025 | Stake report, Schedule 13G/A, by Gregory Boyd Penner | 2.8% of the class | 5%+ stakes | Source |
| November 4, 2025 | Stake report, Schedule 13G/A, by ARK Investment Management LLC | 10.3% of the class | 5%+ stakes | Source |
| August 13, 2025 | Stake report, Schedule 13G/A, by Gregory Boyd Penner | 6.8% of the class | 5%+ stakes | Source |
| July 24, 2025 | Stake report, Schedule 13G/A, by EDMOND DE ROTHSCHILD ASSET MANAGEMENT (FRANCE) | 4.5% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Pacific Biosciences Of California, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Pacific Biosciences Of California, Inc. and the records around it.
Pacific Biosciences Of California, Inc. elsewhere on the record
- 5%+ stake filings Nov 2026
- Layoff notices Aug 2026
- Who owns it
Companies that share a holder
- EDMOND DE ROTHSCHILD ASSET MANAGEMENT (FRANCE) also filed stake reports on 1 other company: ZipRecruiter, Inc. (Apr 2026)
- ARK Investment Management LLC also filed stake reports on 20 other companies: Tempus AI, Inc. (Nov 2026), 10x Genomics, Inc. (Oct 2026), Twist Bioscience Corp (Sep 2026)
- THE GOLDMAN SACHS GROUP, INC. also filed stake reports on 173 other companies: AEON ACQUISITION I CORP. (Nov 2026), ALPEX ACQUISITION CORPORATION (Nov 2026), ARCHIMEDES TECH SPAC PARTNERS II CO. (Nov 2026)
Watch Pacific Biosciences Of California, Inc.
Get an email when Pacific Biosciences Of California, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Pacific Biosciences Of California, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Pacific Biosciences Of California, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Pacific Biosciences Of California, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
12 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-11-04 | In | Chief Accounting Officer | 8-K, 2026-11-04 | ||
| 2026-08-05 | Reported | not named in the filing | 8-K, 2026-08-05 | ||
| 2026-07-09 | Out | Director | 8-K, 2026-07-09 |
Who leads Pacific Biosciences Of California, Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Chief Accounting Officer: Bill Meyer, appointed (filed 2026-11-04).
- Director: Christopher M. Smith, departure reported (filed 2026-07-09). No successor is named in these filings.
New leaders reset buying decisions — get the Full Report on Pacific Biosciences Of California, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Chief Accounting Officer at Pacific Biosciences Of California, Inc., with the record behind each one.
Find candidates like Chief Accounting Officer at Pacific Biosciences Of California, Inc.Every change, in the filing's words
Appointed: Bill Meyer, Chief Accounting Officer
On November 3, 2026, the Board appointed Bill Meyer, age 64, as the Company's Chief Accounting Officer and designated him as the Company's principal accounting officer, effective as of the Effective Date.
- Chief Financial Officer Transition Effective November 3, 2026 (the "Effective Date"), Jim Gibson stepped down as the Chief Financial Officer, principal financial officer and principal accounting officer of the Company and transitioned to a non-executive advisory role[ as an advisor to the Chief Executive Officer].
- Mr. Gibson is expected to remain employed by the Company in that advisory role to assist with the transition of his responsibilities from the Effective Date through March 31, 2027, or such earlier date on which his employment is terminated for cause (the "Transition Period").
- These severance payments and benefits will be in full satisfaction of any severance obligations under Mr. Gibson's Change in Control and Severance Agreement with the Company, dated March 31, 2025.
- The foregoing description is based on the Company's current expectations, and the terms of Mr. Gibson's transition remain subject to the execution of the Transition Agreement.
- If the Transition Agreement is entered into, the Company expects to file a copy as an exhibit to its Annual Report on Form 10-K for the fiscal year ending December 31, 2026.
Reported
On July 30, 2026, the Board appointed Mark Van Oene, age 54, as the Company's President and Chief Executive Officer and as a member of the Board, effective August 5, 2026 (the "Effective Date").
- Mr. Van Oene succeeds Christian Henry, who stepped down as President and Chief Executive Officer as of the Effective Date.
- Mr. Henry will continue to serve on the Board.
- In connection with his appointment as Chief Executive Officer, the Company and Mr. Van Oene entered into an employment agreement (the "Employment Agreement").
- The terms of the Employment Agreement provide that Mr. Van Oene will receive an annual base salary of $743,000, effective August 16, 2026.
- Mr. Van Oene will have an annual target bonus opportunity equal to 100% of his base salary, subject to achieving performance goals established by the Board.
- For 2026, Mr. Van Oene's target bonus opportunity will be based (i) 80% on the Company's achievement of corporate goals and (ii) 20% on certain individual performance criteria.
- The Option will be scheduled to vest monthly over three years measured from the grant date, and the RSU will be scheduled to vest as to 1/3rd of the shares on each anniversary of the grant date, each subject to his continued employment with the Company through each applicable vesting date.
- The number of shares of Common Stock subject to each Award will be determined in accordance with the Company's equity grant policy.
Departing: Christopher M. Smith, Director
On July 8, 2026, Christopher M. Smith, a member of the board of directors (the "Board") of Pacific Biosciences of California, Inc. (the "Company"), notified the Company of his resignation from the Board, effective immediately.
- The Company is not aware of any disagreement between Mr. Smith and the Company on any matter relating to the Company's operations, policies or practices that resulted in Mr. Smith's resignation.
Tools for this story
Each opens in a new tab, filled in for Pacific Biosciences Of California, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.